4//SEC Filing
Mainolfi Nello 4
Accession 0001193125-25-204997
CIK 0001815442other
Filed
Sep 15, 8:00 PM ET
Accepted
Sep 16, 4:11 PM ET
Size
8.3 KB
Accession
0001193125-25-204997
Insider Transaction Report
Form 4
Mainolfi Nello
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
2025-09-16$49.00/sh−30,000$1,470,000→ 660,482 total - Exercise/Conversion
Common Stock
2025-09-16$2.08/sh+30,000$62,400→ 690,482 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-09-16−30,000→ 435,559 totalExercise: $2.08Exp: 2029-11-13→ Common Stock (30,000 underlying)
Footnotes (2)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person.
- [F2]The shares underlying this stock option are fully vested and exercisable.
Documents
Issuer
Kymera Therapeutics, Inc.
CIK 0001815442
Entity typeother
Related Parties
1- filerCIK 0001821189
Filing Metadata
- Form type
- 4
- Filed
- Sep 15, 8:00 PM ET
- Accepted
- Sep 16, 4:11 PM ET
- Size
- 8.3 KB